Daiichi Sankyo and AstraZeneca’s ENHERTU showed objective response rates of 49% and 56% with 5.4…
DUBLIN--(BUSINESS WIRE)--The "Global Chemicals Market (by Category & Region): Insights & Forecast with Potential Impact…
OSLO, Norway--(BUSINESS WIRE)--#AI--Elliptic Labs (OSE: ELABS), a global AI software company and the world leader…
Dean Rogers to Oversee Growth After Integration of Recent Compliance Learning Acquisition from Thomson Reuters…
SHANGHAI--(BUSINESS WIRE)--The Shanghai office of international law firm Dorsey & Whitney has moved to a…
HONG KONG--(BUSINESS WIRE)--#insurance--Despite a sharp increase in catastrophe losses outside their home markets and a…
SolarWinds will showcase its product portfolio and speak on how integrated observability and service management…
Today marks 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal…
Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients…
An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients…